Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition
about
Novel insight into the mechanism of the vitamin K oxidoreductase (VKOR): electron relay through Cys43 and Cys51 reduces VKOR to allow vitamin K reduction and facilitation of vitamin K-dependent protein carboxylationPurification of a vitamin K epoxide reductase that catalyzes conversion of vitamin K 2,3-epoxide to 3-hydroxy-2-methyl-3-phytyl-2,3-dihydronaphthoquinoneProline-rich Gla protein 2 is a cell-surface vitamin K-dependent protein that binds to the transcriptional coactivator Yes-associated proteinVitamin K and hepatocellular carcinoma: The basic and clinicVKORC1 and VKORC1L1: Why do Vertebrates Have Two Vitamin K 2,3-Epoxide Reductases?Reversal of oral anticoagulationThe use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgeryThe vitamin K oxidoreductase is a multimer that efficiently reduces vitamin K epoxide to hydroquinone to allow vitamin K-dependent protein carboxylationBrodifacoum poisoning with toxicokinetic dataOral anticoagulants: pharmacodynamics, clinical indications and adverse effectsThe Active Metabolite of Warfarin (3'-Hydroxywarfarin) and Correlation with INR, Warfarin and Drug Weekly Dosage in Patients under Oral Anticoagulant Therapy: A Pharmacogenetics StudyOral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Incident long-term warfarin use and risk of osteoporotic fractures: propensity-score matched cohort of elders with new onset atrial fibrillation.Review on natural coumarin lead compounds for their pharmacological activityThe management of coumarin-induced over-anticoagulation Annotation.Use of novel oral anticoagulants for the treatment of venous thromboembolism and its considerations in Asian patients.Antithrombotic therapy in cardiac embolism.Abnormal vitamin K metabolism in the presence of normal clotting factor activity in factory workers exposed to 4-hydroxycoumarins.Plasma disposition of vitamin K1 in relation to anticoagulant poisoning.The impact of VKORC1-1639 G>A polymorphism on the maintenance dose of oral anticoagulants for thromboembolic prophylaxis in North India: A pilot studyAntithrombotic medication for cardioembolic stroke preventionPurified vitamin K epoxide reductase alone is sufficient for conversion of vitamin K epoxide to vitamin K and vitamin K to vitamin KH2Stroke Prevention in Atrial Fibrillation: Where are We Now?A chiral HPLC-MS/MS method for simultaneous quantification of warfarin enantiomers and its major hydroxylation metabolites of CYP2C9 and CYP3A4 in human plasmaImpaired warfarin response secondary to high-dose vitamin K1 for rapid anticoagulation reversal: case series and literature review.In vitro and in vivo functional characterization of bovine vitamin K-dependent gamma-carboxylase expressed in Chinese hamster ovary cells.Stroke prevention in atrial fibrillation: concepts and controversiesVKORC1-dependent pharmacokinetics of intravenous and oral phylloquinone (vitamin K1) mixed micelles formulation.Development and Comparison of Warfarin Dosing Algorithms in Stroke PatientsAnticoagulant effect and safety assessment of an aqueous extract of Pseudocedrela kotschyi (Schweinf.) harms and Adenia cissampeloides (Planch. Ex Hook.) harmsThe emerging threat of superwarfarins: history, detection, mechanisms, and countermeasures.Warfarin Dosing and Time Required to Reach Therapeutic International Normalized Ratio in Patients with Hypercoagulable Conditions.Vitamin K epoxide reductase regulation of androgen receptor activity.Serum pharmacokinetics and coagulation aberration induced by sodium dehydroacetate in male and female Wistar rats.Oral anticoagulant-associated intracerebral hemorrhage.Historical perspective and future direction of coagulation research.Non-vitamin K antagonist oral anticoagulants (NOACs): clinical evidence and therapeutic considerations.Anti-thrombotic therapy in patients with atrial fibrillation and intracranial hemorrhage.Pharmacogenetic aspects of coumarinic oral anticoagulant therapies.Review of the Target-Specific Oral Anticoagulants in Development for the Treatment and Prevention of Venous Thromboembolism.
P2860
Q24304387-A3F89D99-2D4D-4539-BCA0-97ED66A0C7A0Q24567978-07E88944-30AC-43F6-8176-7EFD3D820FA7Q24678049-BC7DFCB5-C9E4-4BCC-AFF3-1EF29AA90813Q26783713-1BB94859-5A2C-440A-811B-644BB91504D4Q26799185-EA4C858F-AB38-44DD-9CC7-B41D4BED5D4AQ26827835-B4878943-0268-4CC9-ABC5-779872C53DABQ26828439-FFA147DC-FE31-4C53-8AFF-83321BF0D3BDQ28115117-E9D686BB-0A36-48B2-A088-28B3C0DF3DC7Q28302290-DE6D570E-C663-40BC-8DCD-964BEDBF8A4EQ28319507-CB11E15A-246F-4ABF-9913-B5F436A18110Q28553937-87A321AE-5CCA-42BD-9285-78A9345F75E1Q34252907-3B1E0A40-CB94-497B-8411-35480264A9FDQ34268703-9B89BC9D-E498-4EFB-95FE-AAFC9C564AA9Q34339290-9B6A564E-FD26-4F7B-BFA0-062A803649A9Q34351118-755C5127-57F3-4E65-B1CE-5A7255130D32Q34351204-85683AC5-BE38-41EE-B7C0-3BED57CC2564Q34362901-63393F54-9F54-4FFC-899E-41A126015DCCQ34447134-C069F133-FC5D-429E-8ADF-B02B096156E5Q34621595-C4996733-B8E8-4409-A6C4-1D491B384759Q35073505-C3E2F725-9479-41AD-92FA-09444C415F0BQ35142419-53CC801F-C58A-45A0-A748-43FBE92D7E90Q35221146-90F51733-906F-444F-8BC7-F671B8D4EC68Q35811581-136EE89D-8E4F-49A6-9CB9-F6DD234250B8Q35828065-5BD4B4AE-DF49-44BD-A617-5D1F20CC688FQ35906328-28E2E148-F537-4139-9FDC-6AA3D503B7FFQ36307869-F035F7CB-B312-476D-A0AD-5A14C60EF9BDQ36382375-77C50A12-FB3C-47F7-BD42-141BEC783D0CQ36609814-CB9CC0BB-5ADC-42E3-B865-E31B89F7F549Q36707903-35CAC6DF-E5F9-42A7-BD36-60F4B04AB855Q36810887-0C68809E-0D6B-4468-A4F5-D8E471D85BAAQ37083446-C6341E5F-7E34-449E-8148-D3FC44A33042Q37548255-F3E6A48A-1936-4F84-AC85-39B7A8B0EC22Q37706708-F39220BA-1881-4FE0-9F80-AB92F0F61C25Q37741368-08DEC8BC-10F2-4397-A66D-A9038B230001Q37900185-324D48FD-E7A9-4513-BD3C-9ECC95932E85Q37903961-6E0192B6-C337-4B0B-87B0-366042F70601Q38236215-B3E1F2D0-F319-4273-8E8F-2FFE2F375352Q38236837-F58FDE60-0991-4989-9333-91C9A86FA1B0Q38266460-263DC39A-36B3-4543-86A9-5148C81D98DAQ38336950-433943E1-1579-4A91-8C48-F45A2FAD7E61
P2860
Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition
description
1978 nî lūn-bûn
@nan
1978 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1978 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1978年の論文
@ja
1978年論文
@yue
1978年論文
@zh-hant
1978年論文
@zh-hk
1978年論文
@zh-mo
1978年論文
@zh-tw
1978年论文
@wuu
name
Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition
@ast
Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition
@en
Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition
@nl
type
label
Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition
@ast
Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition
@en
Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition
@nl
prefLabel
Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition
@ast
Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition
@en
Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition
@nl
P2093
P3181
P356
P1433
P1476
Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition
@en
P2093
D S Whitlon
J A Sadowski
J W Suttie
P304
P3181
P356
10.1021/BI00601A003
P407
P577
1978-04-18T00:00:00Z